BSX - Boston Scientific Corp Stock Price, Fair Value and News

67.33USD-0.09 (-0.13%)Market Closed

Market Summary

USD67.33-0.09

Market Closed

-0.13%

BSX Alerts

3 major insider sales recently.

BSX Stock Price

View Fullscreen

BSX RSI Chart

BSX Valuation

Market Cap

98.8B

Price/Earnings (Trailing)

62.05

Price/Sales (Trailing)

6.94

EV/EBITDA

30.9

Price/Free Cashflow

55.12

BSX Price/Sales (Trailing)

BSX Profitability

EBT Margin

13.94%

Return on Equity

8.26%

Return on Assets

4.53%

Free Cashflow Yield

1.81%

BSX Fundamentals

BSX Revenue

Revenue (TTM)

14.2B

Rev. Growth (Yr)

14.9%

Rev. Growth (Qtr)

5.61%

BSX Earnings

Earnings (TTM)

1.6B

Earnings Growth (Yr)

260%

Breaking Down BSX Revenue

Last 7 days

-1.1%

Last 30 days

-0.2%

Last 90 days

10.5%

Trailing 12 Months

28.0%

How does BSX drawdown profile look like?

BSX Financial Health

Current Ratio

1.32

Debt/Equity

0.44

Debt/Cashflow

0.29

BSX Investor Care

Shares Dilution (1Y)

2.25%

Diluted EPS (TTM)

1.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	13.0B	13.4B	13.8B	14.2B
2022	12.2B	12.3B	12.6B	12.7B
2021	10.1B	11.2B	11.5B	11.9B
2020	10.8B	10.2B	10.1B	9.9B
2019	9.9B	10.1B	10.4B	10.7B
2018	9.3B	9.5B	9.7B	9.8B
2017	8.6B	8.7B	8.8B	9.0B
2016	7.7B	8.0B	8.2B	8.4B
2015	7.4B	7.3B	7.4B	7.5B
2014	7.2B	7.2B	7.3B	7.4B
2013	7.1B	7.1B	7.1B	7.1B
2012	7.6B	7.4B	7.3B	7.2B
2011	7.8B	7.8B	7.8B	7.6B
2010	8.1B	8.0B	7.9B	7.8B
2009	8.0B	8.1B	8.1B	8.2B
2008	0	8.3B	8.2B	8.1B
2007	0	0	0	8.4B

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Boston Scientific Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	carruthers wendy	acquired	82,305	19.3069	4,263	evp, human resources
Apr 01, 2024	sorenson john bradley	sold	-1,133,070	69.2966	-16,351	evp, global operations
Apr 01, 2024	carruthers wendy	sold	-477,777	68.42	-6,983	evp, human resources
Apr 01, 2024	sorenson john bradley	acquired	266,685	16.31	16,351	evp, global operations
Mar 18, 2024	mirviss jeffrey b.	sold	-963,930	66.4504	-14,506	evp&pres, periph intervent
Mar 01, 2024	carruthers wendy	acquired	82,305	19.3069	4,263	evp, human resources
Mar 01, 2024	carruthers wendy	sold	-463,322	66.35	-6,983	evp, human resources
Feb 26, 2024	butcher arthur c	acquired	89,542	21.396	4,185	evp& grp pres, medsurg & apac
Feb 26, 2024	butcher arthur c	sold	-626,098	67.07	-9,335	evp& grp pres, medsurg & apac
Feb 23, 2024	carruthers wendy	sold	-467,093	66.89	-6,983	evp, human resources

Which funds bought or sold BSX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	MV CAPITAL MANAGEMENT, INC.	added	1.84	8,419	49,176	0.01%
Apr 18, 2024	SJS Investment Consulting Inc.	added	33.78	5,005	13,562	-%
Apr 18, 2024	MorganRosel Wealth Management, LLC	unchanged	-	54,083	346,833	0.12%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	11,043	70,819	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	added	14.88	7,000	26,000	-%
Apr 18, 2024	CULLINAN ASSOCIATES INC	unchanged	-	304,380	1,951,960	0.11%
Apr 18, 2024	WOLFF WIESE MAGANA LLC	reduced	-71.43	-5,354	2,740	-%
Apr 18, 2024	STATE OF MICHIGAN RETIREMENT SYSTEM	added	0.12	4,315,940	27,492,400	0.15%
Apr 18, 2024	Dixon Mitchell Investment Counsel Inc.	new	-	6,986	6,986	-%
Apr 18, 2024	PayPay Securities Corp	reduced	-29.89	-864	4,178	0.21%

Are Funds Buying or Selling BSX?

Are funds buying BSX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BSX

No. of Funds

BSX Alerts

3 major insider sales recently.

Unveiling Boston Scientific Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.56%	125,449,595	SC 13G/A
Feb 09, 2024	massachusetts financial services co /ma/	3.9%	57,175,974	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 25, 2024	blackrock inc.	8.7%	127,036,665	SC 13G/A
Feb 14, 2023	blackrock inc.	9.6%	137,802,646	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.29%	118,773,794	SC 13G/A
Feb 08, 2023	massachusetts financial services co /ma/	5.8%	82,467,469	SC 13G/A
Feb 06, 2023	wellington management group llp	4.03%	57,736,340	SC 13G/A
Jan 24, 2023	blackrock inc.	9.8%	140,116,265	SC 13G/A

Recent SEC filings of Boston Scientific Corp

View All Filings

Date Filed	Form Type	Document
Apr 04, 2024	8-K	Current Report
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 20, 2024	ARS	ARS
Mar 20, 2024	DEF 14A	DEF 14A
Mar 20, 2024	DEFA14A	DEFA14A
Mar 19, 2024	4	Insider Trading
Mar 18, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Boston Scientific Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.2B	40.1B	-3.77%	-2.76%	32.53	4.64	-8.12%	-17.45%
BDX	67.7B	19.5B	-1.53%	-10.57%	53.87	3.47	4.02%	-22.04%
ALGN	22.5B	3.9B	-9.16%	-15.16%	50.45	5.81	3.42%	23.09%
BAX	20.0B	14.8B	-5.62%	-8.72%	7.55	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.49%	17.01%	32.32	2.64	4.97%	18.89%
HSIC	9.1B	12.3B	-5.22%	-14.61%	21.9	0.74	-2.44%	-22.68%
BIO	8.2B	2.7B	-16.90%	-39.13%	-12.81	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.41%	-25.34%	-47.02	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-2.66%	12.41%	-562.39	9.32	33.86%	89.83%
PDCO	2.3B	6.6B	-4.93%	-3.92%	12.04	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-14.38%	-20.49%	-1.83	0.39	7.73%	-1066.14%
ANIK	383.3M	166.7M	0.86%	-5.21%	-4.64	2.3	6.67%	-456.34%
ANGO	250.3M	324.0M	11.81%	-29.38%	-1.3	0.77	-3.19%	-337.41%
APYX	45.7M	52.3M	-28.65%	-55.25%	-2.44	0.87	17.61%	19.28%
AEMD	3.8M	3.7M	-10.98%	147.46%	-0.31	1.02	5.77%	8.23%

Boston Scientific Corp News

Latest updates

Boston Scientific Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	5.6%	3,725	3,527	3,599	3,389	3,242	3,170	3,244	3,026	3,127	2,932	3,077	2,752	2,709	2,659	2,003	2,543	2,904	2,707	2,631	2,493	2,561
Gross Profit	6.3%	2,579	2,426	2,542	2,349	2,232	2,191	2,233	2,071	2,155	2,032	2,132	1,858	1,709	1,790	1,212	1,737	2,054	1,930	1,873	1,763	1,833
Operating Expenses	15.1%	1,995	1,733	2,028	1,797	1,830	1,833	1,810	1,605	1,975	1,645	1,870	1,488	1,659	1,995	1,283	1,591	1,844	1,547	1,489	1,222	1,512
S&GA Expenses	11.0%	1,379	1,242	1,354	1,215	1,163	1,132	1,165	1,060	1,153	1,066	1,121	1,019	1,027	984	798	978	1,092	1,012	968	869	953
EBITDA Margin	0.4%	0.24*	0.24*	0.22*	0.22*	0.22*	0.20*	0.22*	0.21*	0.21*	0.24*	0.18*	0.17*	-	-	-	-	-	-	-	-	-
Interest Expenses	-2.3%	65.00	66.00	70.00	65.00	64.00	63.00	64.00	279	87.00	86.00	86.00	82.00	96.00	86.00	91.00	88.00	180	95.00	89.00	109	65.00
Income Taxes	-99.0%	1.00	105	156	131	256	57.00	85.00	45.00	26.00	64.00	-37.00	-16.00	96.00	-72.00	-33.00	12.00	-4,002	-35.00	-9.00	33.00	-90.00
Earnings Before Taxes	-17.2%	505	610	426	444	396	245	345	156	119	483	149	325	307	-227	-181	22.00	-6.00	91.00	145	457	296
EBT Margin	2.2%	0.14*	0.14*	0.11*	0.11*	0.09*	0.07*	0.09*	0.07*	0.09*	0.11*	0.05*	0.02*	-	-	-	-	-	-	-	-	-
Net Income	0%	504	504	270	314	140	188	260	110	95.00	419	186	341	210	-155	-147	11.00	3,996	126	154	424	386
Net Income Margin	25.2%	0.11*	0.09*	0.07*	0.07*	0.06*	0.05*	0.07*	0.07*	0.09*	0.10*	0.05*	0.02*	-	-	-	-	-	-	-	-	-
Free Cashflow	35.8%	690	508	515	79.00	595	320	202	-179	212	358	537	209	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	3.2%	35,136	34,043	33,601	32,892	32,469	31,947	32,189	32,337	32,229	31,877	31,168	30,900	30,777	30,845	30,823	30,113	30,565	26,756	24,309	23,802	20,999
Current Assets	0.2%	6,514	6,504	5,886	5,704	5,760	5,144	5,083	5,065	6,317	6,229	6,758	6,101	6,694	6,160	5,803	4,823	4,699	4,847	6,334	6,234	4,003
Cash Equivalents	-9.1%	865	952	426	570	928	338	276	325	1,925	1,947	2,675	2,016	1,995	2,022	1,724	370	607	277	123	139	829
Inventory	3.3%	2,484	2,404	2,250	2,050	1,867	1,788	1,752	1,736	1,610	1,603	1,430	1,407	1,351	1,472	1,516	1,628	1,579	1,566	1,300	1,228	1,166
Net PPE	8.5%	2,859	2,635	2,534	2,478	2,446	2,273	2,246	2,265	2,252	2,109	2,082	2,053	2,084	2,064	2,079	2,098	2,079	1,942	1,820	1,782	1,782
Goodwill	5.7%	14,387	13,608	13,659	13,269	12,920	12,852	12,883	12,949	11,988	11,820	10,874	10,868	9,951	10,137	10,101	10,098	10,176	10,015	8,451	8,179	7,911
Current Liabilities	7.7%	4,933	4,579	4,562	4,083	3,803	3,549	3,883	4,275	4,274	4,022	4,073	3,393	3,681	3,302	3,108	3,976	4,866	4,254	4,850	4,479	5,260
Long Term Debt	2.2%	8,571	8,386	8,494	8,495	8,915	8,564	8,802	9,067	8,804	8,824	8,847	9,082	9,130	9,325	9,278	9,331	8,592	9,590	7,591	7,590	4,803
Shareholder's Equity	2.1%	19,282	18,886	17.00	178	17,573	17,640	17,251	16,735	16,622	16,462	237	17.00	19,732	15,564	17.00	16.00	270	17,510	17,422	87.00	17,346
Retained Earnings	160.0%	819	315	-189	-450	-750	-876	-1,050	-1,296	-1,392	-1,473	-1,878	-2,050	-2,378	-2,574	-2,405	-2,252	-2,253	-6,249	-6,375	-6,528	-6,953
Additional Paid-In Capital	0.4%	20,647	20,573	20,441	20,356	20,289	20,219	20,103	20,043	19,986	19,930	19,817	19,750	19,732	19,687	19,590	17,589	17,561	17,510	17,422	17,374	17,346
Shares Outstanding	0.3%	1,453	1,449	1,441	1,436	1,431	1,432	1,429	1,428	1,422	1,421	1,420	1,419	-	-	-	-	-	-	-	-	-
Minority Interest	2.1%	248	243	259	259	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	79,000	-	-	-	-	-	-	-	53,200	-	-	-	50,000	-	-	-	53,100	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	37.1%	957	698	658	190	807	470	307	-58.00	478	465	643	284	673	643	269	-77.00	692	502	292	350	19.00
Share Based Compensation	0%	59.00	59.00	60.00	55.00	55.00	58.00	55.00	52.00	49.00	51.00	47.00	47.00	42.00	40.00	46.00	42.00	41.00	42.00	38.00	36.00	36.00
Cashflow From Investing	-434.5%	-1,053	-197	-840	-484	-183	-225	-29.00	-1,574	-461	-1,207	-	71.00	-147	-129	-59.00	-76.00	-49.00	-3,962	-620	-410	-595
Cashflow From Financing	-6.2%	15.00	16.00	43.00	-69.00	1.00	-199	-344	-6.00	-8.00	6.00	2.00	-95.00	-819	-249	1,105	256	-724	1,314	256	2,127	425
Dividend Payments	-	-	-	14.00	14.00	13.00	14.00	14.00	14.00	13.00	14.00	14.00	14.00	-	-	-	-	-	-	-	-	-

BSX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net sales	$ 14,240	$ 12,682	$ 11,888
Cost of products sold	4,345	3,956	3,711
Gross profit	9,896	8,727	8,177
Operating expenses:
Selling, general and administrative expenses	5,190	4,520	4,359
Research and development expenses	1,414	1,323	1,204
Royalty expense	46	47	49
Amortization expense	828	803	741
Intangible asset impairment charges	58	132	370
Contingent consideration net expense (benefit)	58	35	(136)
Restructuring net charges (credits)	69	24	40
Litigation-related net charges (credits)	(111)	173	430
Loss (Gain) on Disposal of Businesses and Assets	0	22	(78)
Operating expenses	7,553	7,078	6,978
Operating income (loss)	2,343	1,649	1,199
Other income (expense):
Interest expense	(265)	(470)	(341)
Other, net	(93)	(38)	218
Income (loss) before income taxes	1,985	1,141	1,076
Income tax expense (benefit)	393	443	36
Net income (loss)	1,592	698	1,041
Preferred stock dividends	23	55	55
Net income (loss) attributable to noncontrolling interests	(1)	0	0
Net income (loss) attributable to Boston Scientific common stockholders	$ 1,570	$ 642	$ 985
Net income (loss) per common share — basic	$ 1.08	$ 0.45	$ 0.69
Net income (loss) per common share — diluted	$ 1.07	$ 0.45	$ 0.69
Weighted-average shares outstanding
Basic	1,453,000	1,430,500	1,422,300
Diluted	1,463,500	1,439,700	1,433,800

BSX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 865	$ 928
Trade accounts receivable, net	2,228	1,970
Inventories	2,484	1,867
Prepaid income taxes	315	264
Other current assets	621	731
Total current assets	6,514	5,760
Property, plant and equipment, net	2,859	2,446
Goodwill	14,387	12,920
Other intangible assets, net	6,003	5,902
Deferred tax assets	3,841	3,942
Other long-term assets	1,531	1,500
TOTAL ASSETS	35,136	32,469
Current liabilities:
Current debt obligations	531	20
Accounts payable	942	862
Accrued expenses	2,646	2,160
Other current liabilities	814	761
Total current liabilities	4,933	3,803
Long-term debt	8,571	8,915
Deferred tax liabilities	134	144
Other long-term liabilities	1,967	2,035
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value - authorized 50,000,000 shares; 0 shares issued as of December 31, 2023 and 10,062,500 shares issued as of December 31, 2022	0	0
Common stock, $0.01 par value - authorized 2,000,000,000 shares; 1,729,000,224 shares issued as of December 31, 2023 and 1,696,633,993 shares issued as of December 31, 2022	17	17
Treasury stock, at cost - 263,289,848 shares as of December 31, 2023 and 2022	(2,251)	(2,251)
Additional paid-in capital	20,647	20,289
Retained earnings (Accumulated deficit)	819	(750)
Accumulated other comprehensive income (loss), net of tax:	49	269
Equity, Attributable to Parent	19,282	17,573
Noncontrolling interests	248	0
Total stockholders’ equity	19,530	17,573
TOTAL LIABILITIES AND EQUITY	$ 35,136	$ 32,469

About Boston Scientific Corp

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

CEO	Mr. Michael F. Mahoney
WEBSITE	bostonscientific.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	45000

Boston Scientific Corp Frequently Asked Questions

What is the ticker symbol for Boston Scientific Corp? What does BSX stand for in stocks?

BSX is the stock ticker symbol of Boston Scientific Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Boston Scientific Corp (BSX)?

As of Fri Apr 19 2024, market cap of Boston Scientific Corp is 98.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BSX stock?

You can check BSX's fair value in chart for subscribers.

What is the fair value of BSX stock?

You can check BSX's fair value in chart for subscribers. The fair value of Boston Scientific Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Boston Scientific Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BSX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Boston Scientific Corp a good stock to buy?

The fair value guage provides a quick view whether BSX is over valued or under valued. Whether Boston Scientific Corp is cheap or expensive depends on the assumptions which impact Boston Scientific Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BSX.

What is Boston Scientific Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, BSX's PE ratio (Price to Earnings) is 62.05 and Price to Sales (PS) ratio is 6.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BSX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Boston Scientific Corp's stock?

In the past 10 years, Boston Scientific Corp has provided 0.172 (multiply by 100 for percentage) rate of return.